Clinical trials: Resistant Hypertension
Hypertension
A Multicenter Study to Evaluate the ROX Arteriovenous Coupler in Patients With Treatment-Resistant Hypertension
The purpose of this study is to evaluate the safety and performance of the ROX COUPLER in patients with treatment-resistant hypertension.
- Trial name
- NCT01642498
- Testing
- ROX COUPLER
- Where
- 18 sites in Belgium, Germany and 5 more
- Volunteers
- 100 people
- Sponsor
- ROX Medical, Inc.
Hypertension
Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
The Study objective is to assess the performance of the Vessix V2 Renal Denervation System for the treatment of uncontrolled hypertension using an innovative percutaneous Radio Frequency (RF) balloon catheter renal denervation…
- Trial name
- REDUCE-HTN (NCT01541865)
- Testing
- Renal Denervation
- Where
- 26 sites in Australia, Austria and 6 more
- Volunteers
- 146 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Arterial Hypertension
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension.
- Trial name
- EPIMODE (NCT07761572)
- Testing
- CS1
- Volunteers
- 126 people
- Sponsor
- Cereno Scientific AB
Uncontrolled Hypertension
Netrod-Pilot Study of Renal Denervation With NetrodTM Sixelectrode Radiofrequency RDN System
This single-arm, non-randomized, open-label investigation aims to collect safety and efficacy data of the CE-Marked Netrod™ RDN System in treating European patients with primary hypertension in the absence of anti-hypertensive…
- Trial name
- NCT07061054
- Testing
- Netrod™ six-electrode radiofrequency renal denervation system
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Patients, Resistant Hypertension
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
- Trial name
- NCT02515331
- Testing
- LHW090
- Where
- 16 sites in United States, Denmark and 4 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Resistant Hypertension, Difficult to Control Hypertension
Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects
A randomized, double-blind, placebo-controlled multiple ascending dose study in hypertensive subjects on stable doses of at least three hypertensive drugs for at least 6 weeks prior to Screening.
- Trial name
- DTC/RHS (NCT05247528)
- Testing
- MANP
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- E-Star BioTech, LLC
Resistant Hypertension, Uncontrolled Hypertension
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
This is a global, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation with the OneShot Renal Denervation System in patients with uncontrolled hypertension.
- Conditions
- Resistant Hypertension, Uncontrolled Hypertension, Renal Artery Ablation
- Trial name
- RAPID II (NCT01939392)
- Testing
- Renal Denervation (OneShot™ Renal Denervation System)
- Where
- Italy
- Sponsor
- Medtronic Endovascular
Metabolic Syndrome
Regional Observation of the Metabolic Syndrome
The aim of the study, is to assess the prevalence of metabolic syndrome in Italy on a regional basis, defined according to National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATPIII) guidelines criteria.
- Trial name
- ORSA (NCT00874952)
- Where
- Italy
- Volunteers
- 1,600 people
- Sponsor
- AstraZeneca
Hypertension, Resistant Hypertension
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).
- Conditions
- Hypertension, Resistant Hypertension, Uncontrolled Hypertension
- Trial name
- NCT07833098
- Testing
- VB19055 Dose A QD, VB19055 Dose B QD, VB19055 Dose C QD
- Where
- 24 sites in China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Hypertension, Metabolic Syndrome
Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome
A STUDY ON WHETHER AN ANTIHYPERTENSIVE MEDICATION PREVENTS DAMAGE TO WALLS OF VEINS IN FEMALE PATIENTS WITH THE METABOLIC SYNDROME (OVERWEIGHT AND OTHER DISORDERS).
- Trial name
- NCT00241150
- Testing
- VALSARTAN
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novartis
Hypertension Resistant to Conventional Therapy
A Study to Evaluate Safety and Efficacy of the Redy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension
The ReDy™ System (Renal Dynamics) is a renal denervation device incorporating a variety of ablation features and technical improvements over previously designed systems into a single product.
- Trial name
- NCT02690909
- Testing
- Redy™ Renal Denervation System
- Where
- 10 sites in Belgium, Germany and 6 more
- Volunteers
- 55 people
- Sponsor
- Renal Dynamics GmbH
Hypertension, Type 2 Diabetes
Multi-Organ Denervation With the iRF System to RedUce Sympathetic Drive
The objective of the study is to evaluate the safety of multi-organ denervation using the Integrated Radio Frequency (iRF) Denervation System. and to understand any potential improvement in hypertension and glycemic control.
- Conditions
- Hypertension, Type 2 Diabetes, Metabolic Syndrome
- Trial name
- MODUS (NCT04917393)
- Testing
- iRF System Multi-organ Denervation, Control Procedure
- Where
- 2 sites in Georgia
- Volunteers
- 45 people
- Sponsor
- Metavention
Resistant Hypertension
Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.
Hypertension is a serious public health issue, affecting approximately 30% of adults. Hypertension greatly contributes to the risk for heart disease and stroke, both among the top three leading causes of death in the Americas…
- Trial name
- NCT02926495
- Testing
- eCoin System
- Sponsor
- Valencia Technologies Corporation
PAH, Pulmonary Hypertension
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03683186
- Testing
- Ralinepag
- Where
- 190 sites in United States, Argentina and 31 more
- Volunteers
- 1,000 people
- Sponsor
- United Therapeutics
Prehypertension, Elevated Blood Pressure
Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure
This clinical study aims to assess the efficacy of TOTUM-854, a mix of 6 plant extracts, consumed twice a day on automated office blood pressure in subjects with moderately elevated blood pressure.
- Conditions
- Prehypertension, Elevated Blood Pressure, Blood Pressure, Metabolic Syndrome
- Trial name
- INSIGHT (NCT05469503)
- Testing
- TOTUM-854
- Where
- 10 sites in Bulgaria, France and 1 more
- Volunteers
- 410 people
- Sponsor
- Valbiotis